Literature DB >> 27941539

Primary Salivary Gland Type Tumors of the Thymus.

Neda Kalhor1, Annikka Weissferdt, Cesar A Moran.   

Abstract

The existence of primary salivary gland type tumors (SGTs), similar to those occurring in the major salivary glands, is well known in the thoracic cavity. When they occur in this anatomic area, these tumors more commonly arise from the lung. However, the existence of these tumors primarily affecting the thymus, although recognized in the literature, is rather not well documented or known. In addition, contrary to the primary lung SGTs, which are predominantly of the malignant type, these tumors when occur in thymus encompass a wider spectrum of biology ranging from benign to low grade, and high grade malignancy. The recognition of SGTs in the thymus, even though rare, is important to properly address treatment and prognosis. Herein, we will discuss the numerous benign a malignant SGTs that have been described in the thymus and highlight the difficulty that these tumors may pose when occurring in the thymic area.

Entities:  

Mesh:

Year:  2017        PMID: 27941539     DOI: 10.1097/PAP.0000000000000132

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  3 in total

Review 1.  Clinicopathologic and genetic features of primary bronchopulmonary mucoepidermoid carcinoma: the MD Anderson Cancer Center experience and comprehensive review of the literature.

Authors:  Alireza Salem; Diana Bell; Boris Sepesi; Vassiliki Papadimitrakopoulou; Adel El-Naggar; Cesar A Moran; Neda Kalhor
Journal:  Virchows Arch       Date:  2017-03-25       Impact factor: 4.064

Review 2.  Common and rare carcinomas of the thymus.

Authors:  Anja C Roden; Malgorzata Szolkowska
Journal:  Virchows Arch       Date:  2021-01-03       Impact factor: 4.064

3.  Postoperative radiotherapy for thymus salivary gland carcinoma: A case report.

Authors:  Rui Deng; Nan-Jing Li; Liang-Liang Bai; Shi-Hong Nie; Xiao-Wen Sun; Yong-Sheng Wang
Journal:  World J Clin Cases       Date:  2022-09-16       Impact factor: 1.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.